Cargando…

Pharmacological treatment of chronic obstructive pulmonary disease

None of the drugs currently available for chronic obstructive pulmonary disease (COPD) are able to reduce the progressive decline in lung function which is the hallmark of this disease. Smoking cessation is the only intervention that has proved effective. The current pharmacological treatment of COP...

Descripción completa

Detalles Bibliográficos
Autor principal: Montuschi, Paolo
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2707800/
https://www.ncbi.nlm.nih.gov/pubmed/18044097
_version_ 1782169184887635968
author Montuschi, Paolo
author_facet Montuschi, Paolo
author_sort Montuschi, Paolo
collection PubMed
description None of the drugs currently available for chronic obstructive pulmonary disease (COPD) are able to reduce the progressive decline in lung function which is the hallmark of this disease. Smoking cessation is the only intervention that has proved effective. The current pharmacological treatment of COPD is symptomatic and is mainly based on bronchodilators, such as selective β(2)-adrenergic agonists (short- and long-acting), anticholinergics, theophylline, or a combination of these drugs. Glucocorticoids are not generally recommended for patients with stable mild to moderate COPD due to their lack of efficacy, side effects, and high costs. However, glucocorticoids are recommended for severe COPD and frequent exacerbations of COPD. New pharmacological strategies for COPD need to be developed because the current treatment is inadequate.
format Text
id pubmed-2707800
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-27078002009-07-27 Pharmacological treatment of chronic obstructive pulmonary disease Montuschi, Paolo Int J Chron Obstruct Pulmon Dis Reviews None of the drugs currently available for chronic obstructive pulmonary disease (COPD) are able to reduce the progressive decline in lung function which is the hallmark of this disease. Smoking cessation is the only intervention that has proved effective. The current pharmacological treatment of COPD is symptomatic and is mainly based on bronchodilators, such as selective β(2)-adrenergic agonists (short- and long-acting), anticholinergics, theophylline, or a combination of these drugs. Glucocorticoids are not generally recommended for patients with stable mild to moderate COPD due to their lack of efficacy, side effects, and high costs. However, glucocorticoids are recommended for severe COPD and frequent exacerbations of COPD. New pharmacological strategies for COPD need to be developed because the current treatment is inadequate. Dove Medical Press 2006-12 2006-12 /pmc/articles/PMC2707800/ /pubmed/18044097 Text en © 2006 Dove Medical Press Limited. All rights reserved
spellingShingle Reviews
Montuschi, Paolo
Pharmacological treatment of chronic obstructive pulmonary disease
title Pharmacological treatment of chronic obstructive pulmonary disease
title_full Pharmacological treatment of chronic obstructive pulmonary disease
title_fullStr Pharmacological treatment of chronic obstructive pulmonary disease
title_full_unstemmed Pharmacological treatment of chronic obstructive pulmonary disease
title_short Pharmacological treatment of chronic obstructive pulmonary disease
title_sort pharmacological treatment of chronic obstructive pulmonary disease
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2707800/
https://www.ncbi.nlm.nih.gov/pubmed/18044097
work_keys_str_mv AT montuschipaolo pharmacologicaltreatmentofchronicobstructivepulmonarydisease